-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MBl/OPhuqpkVLRxoboKs6uYr5yogWvDsg3XpepQsv546412EbRGYL8g56K7onhml rmmp5OiGjQA8J+z7F1Y9lQ== 0000922423-99-000266.txt : 19990217 0000922423-99-000266.hdr.sgml : 19990217 ACCESSION NUMBER: 0000922423-99-000266 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990216 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE CENTRAL INDEX KEY: 0000094784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870277826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-07547 FILM NUMBER: 99541830 BUSINESS ADDRESS: STREET 1: 31 NEWBURY ST STREET 2: SUITE 300 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6174250200 MAIL ADDRESS: STREET 1: 31 NEWBURY STREET STREET 2: SUITE 300 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE DATE OF NAME CHANGE: 19790521 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ROSENWALD LINDSAY A MD CENTRAL INDEX KEY: 0000941841 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 375 PARK AVE STREET 2: SUITE 1501 CITY: NEW YORK STATE: NY ZIP: 10152 BUSINESS PHONE: 2128324366 MAIL ADDRESS: STREET 1: 375 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10152 FORMER COMPANY: FORMER CONFORMED NAME: ROSENWALD LINDSAY MD DATE OF NAME CHANGE: 19950316 SC 13G/A 1 SCHEDULE 13G AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ----------------------------------------- SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 ----------------------------------------- Boston Life Sciences, Inc. ----------------------------------------- (Name of Issuer) Common Stock, par value $0.01 per share ------------------------------------------ (Title of Class of Securities) 100843408 ------------- (CUSIP Number) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes to Schedule 13G). 1 SCHEDULE 13G CUSIP No. 100843408 Page 2 of 5 - -------------------------------------------------------------------------------- 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Lindsay A. Rosenwald, M.D. - -------------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP (a) |_| (b) |_| - -------------------------------------------------------------------------------- 3) SEC USE ONLY - -------------------------------------------------------------------------------- 4) CITIZENSHIP OR PLACE OF ORGANIZATION United States - -------------------------------------------------------------------------------- 5) SOLE VOTING POWER 345,504 NUMBER ---------------------------------------------------------- OF 6) SHARED VOTING POWER SHARES 54,052 /1/ BENEFICIALLY ---------------------------------------------------------- OWNED BY 7) SOLE DISPOSITIVE POWER EACH 345,504 /1/ REPORTING ---------------------------------------------------------- PERSON 8) SHARED DISPOSITIVE POWER WITH 54,052 - -------------------------------------------------------------------------------- 9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 399,556 /2/ - -------------------------------------------------------------------------------- 10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] - -------------------------------------------------------------------------------- 11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.00% - -------------------------------------------------------------------------------- 12) TYPE OF REPORTING PERSON IN - -------------------------------------------------------------------------------- - -------- 1 Includes 27,027 shares of common stock of the Issuer and warrants to purchase 9,009 shares of common stock of the Issuer held by Aries Domestic Fund, L.P. (the "Partnership") and 13,512 shares of common stock of the issuer and warrants to purchase 4,504 shares of Common Stock of the Issuer held by The Aries Master Fund, a Cayman Island exempted company (the "Master Fund"). Paramount Capital Asset Management, Inc. ("PCAM") is the general partner of the Partnership and the investment manager of the Master Fund. Dr. Rosenwald is the chairman and sole shareholder of PCAM. 2 Does not include 10,801 shares of common stock of the Issuer held by Dr. Rosenwald's wife in trust for the benefit of his minor children, for which Dr. Rosenwald disclaims beneficial ownership. 2 Item 1. (a) Name of Issuer: Boston Life Sciences, Inc. (the "Company") (b) Address of Issuer's Principal Executive Offices: Boston Life Sciences, Inc. 31 Newbury Street, Ste. 300 Boston, MA 02116 Item 2. (a) Name of Person Filing: Lindsay A. Rosenwald, M.D. (b) Address of Principal Business Office or, if None, Residence: Paramount Capital 787 Seventh Avenue, 48th Floor New York, New York 10019 (c) Citizenship: Dr. Rosenwald is a citizen of the United States. (d) Title of Class of Securities: Common Stock, $0.01 par value ("shares"). (e) CUSIP#: 452525306 Item 3. Check the box if this statement is filed pursuant to Rule 13d-1(c) [ ] Item 4. Ownership: For information concerning the ownership of Common Stock of the Company by the Reporting Persons, see Items 5 through 9 and 11 of the cover pages to this schedule 13G and footnotes thereto. Item 5. Ownership of Five Percent or Less of a Class: As of the date of the filing of this Schedule 13G Amendment, Dr. Rosenwald ceased to be the beneficial owner of more than 5% of the shares 3 of the Issuer. Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported On By the Parent Holding Company: Not applicable. Item 8. Identification and Classification of Members of the Group: Not applicable. Item 9. Notice of Dissolution of Group: Not applicable. Item 10. Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 4 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 16, 1999 New York, NY By /s/ Lindsay A. Rosenwald, M.D. --------------------------------- Lindsay A. Rosenwald, M.D. 5 -----END PRIVACY-ENHANCED MESSAGE-----